2016 Access to Medicine Index
Monday, 17 November 2014
2016 ranking of the top 20 pharmaceutical companies based on their access-to-medicine performances for high-burden diseases in low- and middle-income countries.
The Access to Medicine Index is an independent initiative that ranks the world’s leading pharmaceutical companies according to what they are doing for the millions of people in developing countries who do not have reliable access to medicine.
The 2016 Access to Medicine Index, ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries. It found that GSK, which leads the Index for the fifth time, performs best when it comes to matching its access activities with particular needs within the access to medicine agenda.
GSK is joined at the top of the Index by a closely packed group comprising Johnson & Johnson, Novartis and Merck KGaA. The pharmaceutical industry is extremely diverse, and this is reflected in the way each company approaches access to medicine. However, the four companies in this leadership group share some distinguishing characteristics. They have the most mature access programmes, with well-organised access strategies that support business development in emerging markets, where the need for access to medicine is high. They also show the most evidence of addressing independently identified high-priority needs.
The 2016 Index has assessed the extent to which a company’s access operations are needs-oriented: where actions match specific priorities identified by, for instance, countries, the global health community or the Index. In this regard, the Index analysis reveals uneven performance.